Recombinant antibody mixtures: Production strategies and cost considerations

• Published in: Archives of biochemistry and biophysics 2012-10, Vol.526 (2), p.139-145
• Main Authors: Rasmussen, Søren K., Næsted, Henrik, Müller, Christian, Tolstrup, Anne B., Frandsen, Torben P.
• Format: Article
• Language: English
• Subjects: Animals; Antibodies - genetics; Antibodies - immunology; Antibodies - therapeutic use; Antibody mixtures; antigens; banking; Biotechnology - economics; Biotechnology - methods; business enterprises; Cell banking; Cell line generation; CHO cell lines; Cloning, Molecular - methods; CMC; cost effectiveness; Cost of goods; drugs; Humans; immunoglobulin G; Manufacturing; mixtures; monoclonal antibodies; Protein characterization; Recombinant antibodies; Recombinant Proteins - genetics; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; therapeutics
• ISSN: 0003-9861; 1096-0384
• DOI: 10.1016/j.abb.2012.07.001

► Recombinant antibody mixtures, an important new class of antibody therapeutics. ► Production and characterization strategies of recombinant antibody mixtures. ► Cost effective manufacturing of recombinant antibody mixtures. ► Strategies for multiple actives in a single dose. Recombinant monoclonal antibodies have during the last two decades emerged as a very successful class of biological drugs for the treatment of a variety of different diseases used either as biological mono therapy or in combination with small molecule based drugs. Recombinant antibody mixtures offering targeting of more than one antigen is one of the new promising antibody technologies resulting in higher therapeutic effectiveness and/or broader reactivity. Such recombinant antibody mixtures can in principle be manufactured by different approaches but two main strategies is often applied, either individual manufacturing of the constituent antibodies or single batch manufacturing of the recombinant antibody mixture. Symphogen has developed an expression platform, Sympress™, allowing single batch manufacturing of recombinant antibody mixtures, while other companies are currently using a manufacturing strategy based on production of the individual constituent monoclonal antibodies. An overview and comparison of the different approaches with focus on the challenges in terms of cell banking strategy, manufacturing approach, and strategies for release and characterization will be reviewed in the present manuscript. Furthermore, the two manufacturing approaches are compared based on different parameters such as development timelines, preclinical developmental costs, and manufacturing cost of goods sold (COGS). We conclude that the single batch manufacturing approach expressing a mixture of full length IgG provides a robust and reproducible platform that can be used for cost effective manufacturing of recombinant antibody mixtures.